drugset / Trial / NCT04094909
Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study was to investigate that efficacy and safety of rh-endostatin（Endostar）combined with platinum-based doublet chemotherapy and Pembrolizumab as first line therapy in patients with advanced or metastatic non-small-cell lung cancer.
Timeline
- Start
- 2020-02-06
- Primary completion
- 2022-12-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 15 mg/m2 | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 100 mg/m2 | — |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |
Indications
No indication recorded.